Skip to content
2000
Volume 33, Issue 7
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

Endometrial carcinoma (EC) is a type of cancer that originates in the lining of the uterus, known as the endometrium. It is associated with various treatment options such as surgery, radiation therapy, chemotherapy, and hormone therapy, each presenting unique challenges and limitations. Beta-catenin, a protein involved in the development and progression of several cancers, including EC, plays a crucial role. Abnormal beta-catenin signaling is often linked to the emergence of specific EC subtypes, affecting tumor growth and invasion.

Objectives

The study's objective is to identify compounds targeting the beta-catenin protein for treating endometrial cancer (EC) using drug design. Our approach includes molecular docking to evaluate binding affinities, ADME profiling for pharmacokinetic properties, toxicity assessments, and molecular dynamics simulations to assess compound stability and interactions.

Methods

Approximately one thousand anti-cancer phytochemicals were sourced from PubChem and subjected to molecular docking simulations against the beta-catenin protein. The compounds were evaluated based on their binding affinities, with the top five selected for further analysis. These five molecules underwent toxicity and ADME profiling. The Prediction of Activity Spectra for Substances (PASS) tool was used to identify compounds targeting CTNNB1. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were employed to establish quantitative structure-activity relationship (QSAR) models for the five CTNNB1 antagonist molecules.

Results

The selected five compounds, namely Pazopanib, Binimetinib, Telatinib, 4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-3-((5-nitrothiazol-2-yl)thio)-1H-1,2,4-triazol-5(4H)-one, and Ribavirin, demonstrated efficacy against CTNN1. MD simulations of the docked complexes confirmed the stability of these drugs in binding to the target protein. All five molecules showed promising safety and effectiveness profiles according to their ADME and toxicity evaluations.

Conclusion

Through a comprehensive screening process employing drug design methods, this study successfully identified five potential human anticancer drug candidates targeting the beta-catenin protein. These findings offer a foundation for further experimental validation and development towards the treatment of EC.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673307257240826111754
2024-09-23
2026-02-26

  • From This Site

    /content/journals/cmc/10.2174/0109298673307257240826111754
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HenleyS. J. WardE. M. ScottS. MaJ. AndersonR. N. FirthA. U. ThomasC. C. IslamiF. WeirH. K. LewisD. R. J. C. Annual report to the nation on the status of cancer, part I: National cancer statistics.Cancer.2020126102225224910.1002/cncr.32802.
     [Google Scholar]
  2. SasoS. ChatterjeeJ. GeorgiouE. DitriA.M. SmithJ.R. Ghaem-MaghamiS. Endometrial cancer.BMJ2011343jul06 2d395410.1136/bmj.d395421734165
     [Google Scholar]
  3. AbdelmaksoudN.M. El-MahdyH.A. IsmailA. ElsakkaE.G.E. El-HusseinyA.A. KhidrE.G. AliE.M. RashedM.H. El-DemerdashF.E.S. DoghishA.S. The role of miRNAs in the pathogenesis and therapeutic resistance of endometrial cancer: A spotlight on the convergence of signaling pathways.Pathol. Res. Pract.202324415441110.1016/j.prp.2023.15441136921547
     [Google Scholar]
  4. UrickM.E. BellD.W. Clinical actionability of molecular targets in endometrial cancer.Nat. Rev. Cancer201919951052110.1038/s41568‑019‑0177‑x31388127
     [Google Scholar]
  5. RingK.L. BrueglA.S. AllenB.A. ElkinE.P. SinghN. HartmanA.R. DanielsM.S. BroaddusR.R. Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort.Mod. Pathol.201629111381138910.1038/modpathol.2016.13527443514
     [Google Scholar]
  6. StoffelE. MukherjeeB. RaymondV.M. TayobN. KastrinosF. SparrJ. WangF. BandipalliamP. SyngalS. GruberS.B. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.Gastroenterology200913751621162710.1053/j.gastro.2009.07.03919622357
     [Google Scholar]
  7. LeeY.C. LheureuxS. OzaA.M. Treatment strategies for endometrial cancer: current practice and perspective.Curr. Opin. Obstet. Gynecol.2017291475810.1097/GCO.000000000000033827941361
     [Google Scholar]
  8. JamiesonA. BosseT. McAlpineJ.N. The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer.Ther. Adv. Med. Oncol.20211310.1177/1758835921103595934408794
     [Google Scholar]
  9. NeriM. PeirettiM. MelisG.B. PirasB. VallerinoV. PaolettiA.M. MadedduC. ScartozziM. MaisV. Systemic therapy for the treatment of endometrial cancer.Expert Opin. Pharmacother.201920162019203210.1080/14656566.2019.165499631451034
     [Google Scholar]
  10. TalhoukA. McAlpineJ.N. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care.Gynecol. Oncol. Res. Pract.2016311410.1186/s40661‑016‑0035‑427999680
     [Google Scholar]
  11. StellooE. BosseT. NoutR.A. MacKayH.J. ChurchD.N. NijmanH.W. LearyA. EdmondsonR.J. PowellM.E. CrosbieE.J. KitchenerH.C. MileshkinL. PollockP.M. SmitV.T. CreutzbergC.L. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; A TransPORTEC initiative.Mod. Pathol.201528683684410.1038/modpathol.2015.4325720322
     [Google Scholar]
  12. McMellenA. WoodruffE. R. CorrB. R. BitlerB. G. MoroneyM. R. Wnt signaling in gynecologic malignancies.Int. J. Mol. Sci.20202112427210.3390/ijms21124272
     [Google Scholar]
  13. LevineD.A. SchultzN. CherniackA.D. AkbaniR. LiuY. ShenH. RobertsonA.G. PashtanI. ShenR. BenzC.C. YauC. LairdP.W. DingL. ZhangW. MillsG.B. KucherlapatiR. MardisE.R. LevineD.A. Integrated genomic characterization of endometrial carcinoma.Nature20134977447677310.1038/nature1211323636398
     [Google Scholar]
  14. AnastasJ.N. MoonR.T. WNT signalling pathways as therapeutic targets in cancer.Nat. Rev. Cancer2013131112610.1038/nrc341923258168
     [Google Scholar]
  15. DihlmannS. von Knebel DoeberitzM. Wnt/?-catenin- pathway as a molecular target for future anti-cancer therapeutics.Int. J. Cancer2005113451552410.1002/ijc.2060915472907
     [Google Scholar]
  16. ReyaT. CleversH. Wnt signalling in stem cells and cancer.Nature2005434703584385010.1038/nature0331915829953
     [Google Scholar]
  17. KonopkaB. Janiec-JankowskaA. CzapczakD. PaszkoZ. BidzińskiM. OlszewskiW. GoludaC. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations.J. Cancer Res. Clin. Oncol.2007133636137110.1007/s00432‑006‑0179‑417219201
     [Google Scholar]
  18. HuangH.N. KuoC.W. LinM.C. MaoT.L. KuoK.T. Frequent CTNNB1 or PIK3CA mutations occurred in endometrial endometrioid adenocarcinoma with high levels of microsatellite instability and loss of MSH2/MSH6 expression.Appl. Immunohistochem. Mol. Morphol.202028428428910.1097/PAI.000000000000074930789355
     [Google Scholar]
  19. WengC.H. WuK.Y. WangC.J. HuangH.J. TsaiC.L. LinC.Y. RoA. LaiC.H. ChaoA.S. WuR.C. ChaoA. Massively parallel sequencing of endometrial lavage specimens for the detection of cancer-associated mutations in atypical and non-atypical endometrial hyperplasia.Front. Med. (Lausanne)20229109078810.3389/fmed.2022.109078836619620
     [Google Scholar]
  20. Matias-GuiuX. PratJ. Molecular pathology of endometrial carcinoma.Histopathology201362111112310.1111/his.1205323240673
     [Google Scholar]
  21. DouY. KawalerE. A. ZhouD. C. GritsenkoM. A. HuangC. BlumenbergL. KarpovaA. PetyukV. A. SavageS. R. SatpathyS. Proteogenomic characterization of endometrial carcinoma.Cell.20201804729748.e2610.1016/j.cell.2020.01.026
     [Google Scholar]
  22. El SabehM. SahaS.K. AfrinS. IslamM.S. BorahayM.A. Wnt/β-catenin signaling pathway in uterine leiomyoma: Role in tumor biology and targeting opportunities.Mol. Cell. Biochem.202147693513353610.1007/s11010‑021‑04174‑633999334
     [Google Scholar]
  23. KiewiszJ. WasniewskiT. KmiecZ. Participation of WNT and β-catenin in physiological and pathological endometrial changes: Association with angiogenesis.BioMed Res. Int.20152015111110.1155/2015/85405626366420
     [Google Scholar]
  24. KurnitK.C. KimG.N. FellmanB.M. UrbauerD.L. MillsG.B. ZhangW. BroaddusR.R. CTNNB1 (beta- catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.Mod. Pathol.20173071032104110.1038/modpathol.2017.1528281553
     [Google Scholar]
  25. WangY. van der ZeeM. FoddeR. BlokL.J. Wnt/Β- catenin and sex hormone signaling in endometrial homeostasis and cancer.Oncotarget20101767468410.18632/oncotarget.20121317462
     [Google Scholar]
  26. LombardiA.P.G. RoyerC. PisolatoR. CavalcantiF.N. LucasT.F.G. LazariM.F.M. PortoC.S. Physiopathological aspects of the Wnt/β-catenin signaling pathway in the male reproductive system.Spermatogenesis201331e2318110.4161/spmg.2318123687614
     [Google Scholar]
  27. PolakisP. Wnt signaling in cancer.Cold Spring Harb Perspect Biol.201245a00805210.1101/cshperspect.a008052
     [Google Scholar]
  28. InestrosaN.C. Montecinos-OlivaC. FuenzalidaM. Wnt signaling: Role in Alzheimer disease and schizophrenia.J. Neuroimmune Pharmacol.20127478880710.1007/s11481‑012‑9417‑523160851
     [Google Scholar]
  29. LuoJ. ChenJ. DengZ.L. LuoX. SongW.X. SharffK.A. TangN. HaydonR.C. LuuH.H. HeT.C. Wnt signaling and human diseases: What are the therapeutic implications?Lab. Invest.20078729710310.1038/labinvest.370050917211410
     [Google Scholar]
  30. RingA. KimY.M. KahnM. Wnt/catenin signaling in adult stem cell physiology and disease.Stem Cell Rev.201410451252510.1007/s12015‑014‑9515‑224825509
     [Google Scholar]
  31. NovellasdemuntL. AntasP. LiV.S.W. Targeting Wnt signaling in colorectal cancer. A review in the theme: cell signaling: Proteins, pathways and mechanisms.Am. J. Physiol. Cell Physiol.20153098C511C52110.1152/ajpcell.00117.201526289750
     [Google Scholar]
  32. PrestwichT.C. MacDougaldO.A. Wnt/β-catenin signaling in adipogenesis and metabolism.Curr. Opin. Cell Biol.200719661261710.1016/j.ceb.2007.09.01417997088
     [Google Scholar]
  33. HouX. TanY. LiM. DeyS.K. DasS.K. Canonical Wnt signaling is critical to estrogen-mediated uterine growth.Mol. Endocrinol.200418123035304910.1210/me.2004‑025915358837
     [Google Scholar]
  34. OnoM. YinP. NavarroA. MoravekM.B. CoonJ.S.V DruschitzS.A. SernaV.A. QiangW. BrooksD.C. MalpaniS.S. MaJ. ErcanC.M. MittalN. MonsivaisD. DysonM.T. YemelyanovA. MaruyamaT. ChakravartiD. KimJ.J. KuritaT. GottardiC.J. BulunS.E. Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth.Proc. Natl. Acad. Sci. USA201311042170531705810.1073/pnas.131365011024082114
     [Google Scholar]
  35. KoreP.P. MuthaM.M. AntreR.V. OswalR.J. KshirsagarS.S. Computer-aided drug design: an innovative tool for modeling.Open J. Med. Chem.20122413914810.4236/ojmc.2012.24017
     [Google Scholar]
  36. WulandariF. AryaniL. IsworoS. J. G. B. SciencesP. Utilization of bamboo water plant ( Equisetum hyemale ) in reducing chemical oxygen demand level of laboratory waste.2018431802310.30574/gscbps.2018.4.3.0065.
     [Google Scholar]
  37. BurleyS.K. BermanH.M. KleywegtG.J. MarkleyJ.L. NakamuraH. VelankarS. Protein Data Bank (PDB): The single Global Macromolecular structure Archive.Methods. Mol. Biol.20171607627641
     [Google Scholar]
  38. PettersenE.F. GoddardT.D. HuangC.C. MengE.C. CouchG.S. CrollT.I. MorrisJ.H. FerrinT.E. UCSF ChimeraX : Structure visualization for researchers, educators, and developers.Protein Sci.2021301708210.1002/pro.394332881101
     [Google Scholar]
  39. TianW. ChenC. LeiX. ZhaoJ. LiangJ. CASTp 3.0: computed atlas of surface topography of proteins.Nucleic Acids Res.201846W1W363W36710.1093/nar/gky47329860391
     [Google Scholar]
  40. YuanS. ChanH.C.S. HuZ. Using PyMOL as a platform for computational drug design.Wiley Interdiscip. Rev. Comput. Mol. Sci.201772e129810.1002/wcms.1298
     [Google Scholar]
  41. KimS. ChenJ. ChengT. GindulyteA. HeJ. HeS. LiQ. ShoemakerB.A. ThiessenP.A. YuB. ZaslavskyL. ZhangJ. BoltonE.E. PubChem 2023 update.Nucleic Acids Res.202351D1D1373D138010.1093/nar/gkac95636305812
     [Google Scholar]
  42. OunthaisongU. TangyuenyongwatanaP. Cross-docking study of flavonoids against tyrosinase enzymes using PyRx 0.8 virtual screening tool.TJPS2017201741
     [Google Scholar]
  43. AdeoyeA.O. OsoB.J. OlaoyeI.F. TijjaniH. AdebayoA.I. Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus.J. Biomol. Struct. Dyn.202139103469347910.1080/07391102.2020.176587632375574
     [Google Scholar]
  44. DallakyanS. OlsonA. J. Small-molecule library screening by docking with PyRx.Methods Mol Biol.201512632435010.1007/978‑1‑4939‑2269‑7_19.
     [Google Scholar]
  45. MorrisG.M. HueyR. OlsonA.J. Using AutoDock for ligand-receptor docking.Curr. Protoc. Bioinformatics2008Chapter 811419085980
     [Google Scholar]
  46. Bitencourt-FerreiraG. de AzevedoW. F. Docking with SwissDock.Methods Mol. Biol.2019205318920210.1007/978‑1‑4939‑9752‑7_12.
     [Google Scholar]
  47. BIOVIA. Discoverey studio visualizerAvailable from: https://discover.3ds.com/discovery-studio-visualizer-download.2008
  48. GoddardT.D. HuangC.C. MengE.C. PettersenE.F. CouchG.S. MorrisJ.H. FerrinT.E. UCSF ChimeraX: Meeting modern challenges in visualization and analysis.Protein Sci.2018271142510.1002/pro.323528710774
     [Google Scholar]
  49. NoorF. RehmanA. AshfaqU.A. SaleemM.H. OklaM.K. Al-HashimiA. AbdElgawadH. AslamS. Integrating network pharmacology and molecular docking approaches to decipher the multi-target pharmacological mechanism of Abrus precatorius L. acting on diabetes.Pharmaceuticals (Basel)202215441410.3390/ph1504041435455411
     [Google Scholar]
  50. RehmanA. NoorF. FatimaI. QasimM. LiaoM. Identification of molecular mechanisms underlying the therapeutic effects of Celosia cristata on immunoglobulin nephropathy.Comput. Biol. Med.2022151Pt A10629010.1016/j.compbiomed.2022.10629036379189
     [Google Scholar]
  51. WesthouseR.A. CarB.D. Pharmacokinetics and safety assessment.Cancer Immunotherapy.Elsevier201318720610.1016/B978‑0‑12‑394296‑8.00013‑0
     [Google Scholar]
  52. NoorF. AsifM. AshfaqU.A. QasimM. Tahir ul QamarM. Machine learning for synergistic network pharmacology: A comprehensive overview.Brief. Bioinform.2023243bbad12010.1093/bib/bbad12037031957
     [Google Scholar]
  53. DainaA. MichielinO. ZoeteV. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.Sci. Rep.2017714271710.1038/srep4271728256516
     [Google Scholar]
  54. BanerjeeP. EckertA.O. SchreyA.K. PreissnerR. ProTox-II: A webserver for the prediction of toxicity of chemicals.Nucleic Acids Res.201846W1W257W26310.1093/nar/gky31829718510
     [Google Scholar]
  55. LaguninA. StepanchikovaA. FilimonovD. PoroikovV. PASS: prediction of activity spectra for biologically active substances.Bioinformatics200016874774810.1093/bioinformatics/16.8.74711099264
     [Google Scholar]
  56. OpoF.A.D.M. RahmanM.M. AhammadF. AhmedI. BhuiyanM.A. AsiriA.M. Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti- cancer agents targeting XIAP protein.Sci. Rep.2021111404910.1038/s41598‑021‑83626‑x33603068
     [Google Scholar]
  57. BowersK.J. ChowE. XuH. DrorR.O. EastwoodM.P. GregersenB.A. KlepeisJ.L. KolossvaryI. MoraesM.A. SacerdotiF.D. Scalable algorithms for molecular dynamics simulations on commodity clusters.Proceedings of the 2006 ACM/IEEE Conference on Supercomputing20068410.1145/1188455.1188544
     [Google Scholar]
  58. AhammadF. AlamR. MahmudR. AkhterS. TalukderE.K. TonmoyA.M. FahimS. Al-GhamdiK. SamadA. QadriI. Pharmacoinformatics and molecular dynamics simulation-based phytochemical screening of neem plant (Azadiractha indica) against human cancer by targeting MCM7 protein.Brief. Bioinform.2021225bbab09810.1093/bib/bbab09833834183
     [Google Scholar]
  59. GenhedenS. RydeU. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities.Expert Opin. Drug Discov.201510544946110.1517/17460441.2015.103293625835573
     [Google Scholar]
  60. BhachooJ. BeumingT. Investigating protein-peptide interactions using the schrödinger computational suite.Methods Mol Biol.2017156123525410.1007/978‑1‑4939‑6798‑8_14.
     [Google Scholar]
  61. LovellS.C. DavisI.W. ArendallW.B.III de BakkerP.I.W. WordJ.M. PrisantM.G. RichardsonJ.S. RichardsonD.C. Structure validation by Cα geometry: ϕ,ψ and Cβ deviation.Proteins200350343745010.1002/prot.1028612557186
     [Google Scholar]
  62. KopardeA.A. DoijadR.C. MagdumC.S. Natural products in drug discovery.Pharmacognosy-Medicinal plants.IntechOpen201810.5772/intechopen.82860
     [Google Scholar]
  63. AnjumF. MohammadT. AlmalkiA.A. AkhtarO. AbdullaevB. HassanM.I. Phytoconstituents and medicinal plants for anticancer drug discovery: Computational identification of potent inhibitors of PIM1 kinase.OMICS202125958059010.1089/omi.2021.010734448628
     [Google Scholar]
  64. MoriceP. LearyA. CreutzbergC. Abu-RustumN. DaraiE. Endometrial cancer.Lancet2016387100231094110810.1016/S0140‑6736(15)00130‑026354523
     [Google Scholar]
  65. LuK.H. BroaddusR.R. Endometrial Cancer.N. Engl. J. Med.2020383212053206410.1056/NEJMra151401033207095
     [Google Scholar]
  66. Madhavi SastryG. AdzhigireyM. DayT. AnnabhimojuR. ShermanW. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments.J. Comput. Aided Mol. Des.201327322123410.1007/s10822‑013‑9644‑823579614
     [Google Scholar]
  67. MacalinoS.J.Y. GosuV. HongS. ChoiS. Role of computer-aided drug design in modern drug discovery.Arch. Pharm. Res.20153891686170110.1007/s12272‑015‑0640‑526208641
     [Google Scholar]
  68. ZhangS. Computer-aided drug discovery and development.Methods Mol Biol.2011716233810.1007/978‑1‑61779‑012‑6_2.
     [Google Scholar]
  69. JiaC.Y. LiJ.Y. HaoG.F. YangG.F. A drug-likeness toolbox facilitates ADMET study in drug discovery.Drug Discov. Today202025124825810.1016/j.drudis.2019.10.01431705979
     [Google Scholar]
  70. LiA.P. Screening for human ADME/Tox drug properties in drug discovery.Drug Discov. Today20016735736610.1016/S1359‑6446(01)01712‑311267922
     [Google Scholar]
  71. ChmielT. MieszkowskaA. Kempińska-KupczykD. Kot-WasikA. NamieśnikJ. MazerskaZ. The impact of lipophilicity on environmental processes, drug delivery and bioavailability of food components.Microchem. J.201914639340610.1016/j.microc.2019.01.030
     [Google Scholar]
  72. NorinderU. BergströmC.A.S. Prediction of ADMET Properties.ChemMedChem20061992093710.1002/cmdc.20060015516952133
     [Google Scholar]
  73. SegallM.D. BarberC. Addressing toxicity risk when designing and selecting compounds in early drug discovery.Drug Discov. Today201419568869310.1016/j.drudis.2014.01.00624451294
     [Google Scholar]
  74. ValerioL.G.Jr. In silico toxicology for the pharmaceutical sciences.Toxicol. Appl. Pharmacol.2009241335637010.1016/j.taap.2009.08.02219716836
     [Google Scholar]
  75. RaiesA.B. BajicV.B. In silico toxicology: Computational methods for the prediction of chemical toxicity.Wiley Interdiscip. Rev. Comput. Mol. Sci.20166214717210.1002/wcms.124027066112
     [Google Scholar]
  76. FieldenM.R. KolajaK.L. The role of early in vivo toxicity testing in drug discovery toxicology.Expert Opin. Drug Saf.20087210711010.1517/14740338.7.2.10718324874
     [Google Scholar]
  77. HouT. WangJ. LiY. WangW. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations.J. Chem. Inf. Model.2011511698210.1021/ci100275a21117705
     [Google Scholar]
  78. RehmanA. FatimaI. WangY. TongJ. NoorF. QasimM. PengY. LiaoM. Unveiling the multi-target compounds of Rhazya stricta : Discovery and inhibition of novel target genes for the treatment of clear cell renal cell carcinoma.Comput. Biol. Med.202316510742410.1016/j.compbiomed.2023.10742437717527
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673307257240826111754
Loading
Discovery of Small Molecule Inhibitors Targeting CTNNB1 (β-catenin) for Endometrial cancer: Employing 3D QSAR, Drug-Likeness Assessment, ADMET Predictions, Molecular Docking and Simulation
Curr. Med. Chem. 33, 1383 (2026); https://doi.org/10.2174/0109298673307257240826111754
/content/journals/cmc/10.2174/0109298673307257240826111754
/content/journals/cmc/10.2174/0109298673307257240826111754
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): beta-catenin; Endometrial carcinoma; molecular docking; molecular dynamics (MD) simulation; QSAR; target protein

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test